Value of 18 F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 6, 2011, Pages 1046-1053

  Haznedar, Rauf ^a   Akı, Sahika Z ^a   Akdemir, Özgür U ^a   Özkurt, Zübeyde N ^a   Çeneli, Özcan ^b   Yağcı, Münci ^a   Sucak, Gulsan T ^a   Ünlü, Mustafa ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Multiple myeloma; PET CT; Survival

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMACYTOMA; PREDICTION; SCORING SYSTEM; BONE MARROW; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY; SCINTISCANNING; SURVIVAL; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; BONE MARROW; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79958066921     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1738-8     Document Type: Article

References (25)

1. SH Landis T Murray S Bolden PA Wingo 1998 Cancer statistics, 1998 CA Cancer J Clin 48 6 29 9449931 10.3322/canjclin.48.1.6 1:STN:280: DyaK1c7htFGrtg%3D%3D (Pubitemid 28045531)
2. International Myeloma Working Group 2003 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group Br J Haematol 121 749 757 10.1046/j.1365-2141.2003.04355.x (Pubitemid 36718191)
3. BG Durie SE Salmon 1975 A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 842 854 1182674 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U 1:STN:280:DyaE28%2FktFCqtA%3D%3D
4. BG Durie 2006 The role of anatomic and functional staging in myloma: description of Durie/Salmon plus staging system Eur J Cancer 42 1539 1543 16777405 10.1016/j.ejca.2005.11.037 (Pubitemid 44137426)
5. S Delorme A Baur-Melnyk 2009 Imaging in multiple myeloma Eur J Radiol 70 401 408 19272726 10.1016/j.ejrad.2009.02.005
6. M Sasaki Y Ichiya Y Kuwabara M Otsuka T Fukumura Y Kawai H Koga K Masuda 1993 Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium-99m-hydroxymethylenediphosphate negative bone tumors J Nucl Med 34 288 290 8429349 1:STN:280:DyaK3s7lsFOisA%3D%3D (Pubitemid 23056410)
7. AM el-Shirbiny H Yeung M Imbriaco J Michaeli H Macapinlac SM Larson 1997 Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma J Nucl Med 38 1208 1210 9255151 1:STN:280:DyaK2szpvFShsA%3D%3D (Pubitemid 27332614)
8. K Orchard S Barrington J Buscombe A Hilson HG Prentice A Mehta 2002 Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma Br J Haematol 117 133 135 11918544 10.1046/j.1365-2141.2002.03407.x (Pubitemid 34304432)
9. H Jadvar PS Conti 2002 Diagnostic utility of FDG PET in multiple myeloma Skeletal Radiol 31 690 694 12483429 10.1007/s00256-002-0580-2 (Pubitemid 36104567)
10. BGM Durie AD Waxman A D'Agnolo CM Williams 2002 Whole-body (18)F-FDG PET identifies high-risk myeloma J Nucl Med 43 1457 1463 12411548 (Pubitemid 35285870)
11. H Schirrmeister M Bommer AK Buck S Müller P Messer D Bunjes H Döhner L Bergmann SN Reske 2002 Initial results in the assessment of multiple myeloma using 18F-FDG PET Eur J Nucl Med Mol Imaging 29 3 361 366 12002711 10.1007/s00259-001-0711-3 1:CAS:528:DC%2BD38XhvVCms70%3D (Pubitemid 34253248)
12. J Bladé D Samson D Reece J Apperley B Björkstrand G Gahrton M Gertz S Giralt S Jagannath D Vesole 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 102 1115 1123 9753033 10.1046/j.1365-2141.1998.00930.x (Pubitemid 28435189)
13. M Dimopoulos E Terpos RL Comenzo P Tosi M Beksac O Sezer, et al. 2009 International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma Leukemia 23 1545 1556 19421229 10.1038/leu.2009.89 1:STN:280:DC%2BD1MngvFamsA%3D%3D
14. S Lütje JWJ de Rooy S Croockewit E Koedam WJG Oyen RA Raymakers 2009 Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma Ann Hematol 88 1161 1168 19763570 10.1007/s00277-009-0829-0
15. L Mileshkin R Blum JF Seymour A Patrikeos RJ Hicks M Prince 2004 A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma Eur J Haematol 72 32 37 14962260 10.1046/j.0902-4441.2004.00177.x 1:STN:280:DC%2BD2c%2FntlKmtQ%3D%3D (Pubitemid 38161110)
16. H Schirrmeister AK Buck L Bergmann SN Reske M Bommer 2003 Positron emission tomography (PET) for staging of solitary plasmacytoma Cancer Biother Radiopharm 18 841 845 14629832 10.1089/108497803770418382 (Pubitemid 37377319)
17. C Nanni E Zamagni M Farsad P Castellucci P Tosi D Cangini, et al. 2006 Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results Eur J Nucl Med Mol Imaging 33 525 531 16453155 10.1007/s00259-005-0004-3
18. RJ Breyer ME Mulligan SE Smith BR Line AZ Badros 2006 Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma Skeletal Radiol 35 632 640 16758246 10.1007/s00256-006-0127-z (Pubitemid 44194492)
19. ME Mulligan AZ Badros 2007 PET/CT and MR imaging in myeloma Skeletal Radiol 36 5 16 16915386 10.1007/s00256-006-0184-3 (Pubitemid 44843162)
20. M Varettoni A Corso G Pica S Mangiacavalli C Pascutto M Lazzarino 2010 Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients Ann Oncol 21 325 330 19633044 10.1093/annonc/mdp329 1:STN:280:DC%2BC3c%2Fls1entQ%3D%3D
21. R Fonti B Salvatore M Quarantelli C Sirignano S Segreto F Petruzziello L Catalano R Liuzzi, et al. 2008 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma J Nucl Med 49 195 200 18199607 10.2967/jnumed.107.045641 (Pubitemid 351225656)
22. J Hur CS Yoon YH Ryu MJ Yun JS Suh 2008 Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma Acta Radiol 49 427 435 18415787 10.1080/02841850801898625 1:STN:280:DC%2BD1c3lsVGltQ%3D%3D (Pubitemid 351598798)
23. DA Dimitrakopoulou-Strauss M Hoffmann R Bergner M Uppenkamp U Haberkorn LG Strauss 2009 Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET Clin Nucl Med 34 576 584 19692817 10.1097/RLU.0b013e3181b06bc5
24. TB Bartel J Haessler LYT Brown JD Shaughnessy F van Rhee E Anaissie, et al. 2009 F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Blood 114 2068 2076 19443657 10.1182/blood-2009-03-213280 1:CAS:528:DC%2BD1MXhtFKksLrM
25. M Castellani M Carletto L Baldini R Calori V Longari D Soligo L Dellavedova P Gerundini 2010 The prognostic value of F-18 fluorodeoxyglucose bone marrow uptake in patients with recent diagnosis of multiple myeloma: a comparative study with Tc-99m sestamibi Clin Nucl Med 35 1 5 20026963 10.1097/RLU.0b013e3181c3619c